Loading publications…
The last 5 uploaded publications
Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders
Flora Peyvandi, Roberta Palla, Marzia Menegatti, Simona Maria Siboni, Susan Halimeh, Britta Faeser, Helen Pergantou, Helen Platokouki, Paul Giangrande, Kathelijne Peerlinck, Tıraje Celkan, Nihal Özdemir, Christoph Bidlingmaier, J. Ingerslev, Muriel Giansily‐Blaizot, Jean‐François Schved, Ruth Gilmore, Alain Gadisseur, Majda Benedik‐Dolničar, Lidija Kitanovski, Danijela Miković, Khaled M. Musallam, Frits R. Rosendaal (2012). Coagulation factor activity and clinical bleeding severity in rare bleeding disorders: results from the European Network of Rare Bleeding Disorders. Journal of Thrombosis and Haemostasis, 10(4), pp. 615-621, DOI: 10.1111/j.1538-7836.2012.04653.x.
Article126 days agoADAMTS‐13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura
Giuseppe Bettoni, Roberta Palla, Carla Valsecchi, Dario Consonni, Luca A. Lotta, Silvia Maria Trisolini, Ilaria Mancini, Khaled M. Musallam, Frits R. Rosendaal, Flora Peyvandi (2012). ADAMTS‐13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Haemostasis, 10(8), pp. 1556-1565, DOI: 10.1111/j.1538-7836.2012.04808.x.
Article126 days agoGenetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis
Frits R. Rosendaal, Roberta Palla, Isabella Garagiola, Pier Mannuccio Mannucci, Flora Peyvandi (2017). Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis. Blood, 130(15), pp. 1757-1759, DOI: 10.1182/blood-2017-06-791756.
Article126 days agoNonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A
Antonino Cannavò, Carla Valsecchi, Isabella Garagiola, Roberta Palla, Pier Mannuccio Mannucci, Frits R. Rosendaal, Flora Peyvandi (2016). Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A. Blood, 129(10), pp. 1245-1250, DOI: 10.1182/blood-2016-06-720086.
Article126 days agoTiming and severity of inhibitor development in recombinant versus plasma‐derived factor VIII concentrates: a SIPPET analysis
Flora Peyvandi, Antonino Cannavò, Isabella Garagiola, Roberta Palla, Pier Mannuccio Mannucci, Frits R. Rosendaal, Amal El‐Beshlawy, Mohsen Saleh Elalfy, Vijay Ramanan, Peyman Eshghi, Suresh Hanagavadi, Ramya Varadarajan, Milad Karimi, Mamta Manglani, Cecil Ross, Guy Young, Tulika Seth, Suneel Apte, Dinesh Nayak, Elena Santagostino, Maria Elisa Mancuso, Adriana C. Sandoval Gonzalez, Johnny Mahlangu, Santiago Bonanad, M. Cerqueira, Nadia P. Ewing, Christoph Male, Tarek Owaidah, Verónica Soto Arellano, Nathan L. Kobrinsky, Suvankar Majumdar, Rosario Garrido, Anupam Sachdeva, Michael A. Simpson, Mathew Thomas, Ezio Zanon, Bülent Antmen, K. Kavakl, Marilyn J. Manco‐Johnson, Mikel Martínez, E. Marzouka, M.G. Mazzucconi, Daniela Neme, A. Palomo Bravo, Rodrigo Aguilera, A. Prezotti, Katharina Schmitt, Brian M. Wicklund, Bülent Zülfikar (2017). Timing and severity of inhibitor development in recombinant versus plasma‐derived factor VIII concentrates: a SIPPET analysis. Journal of Thrombosis and Haemostasis, 16(1), pp. 39-43, DOI: 10.1111/jth.13888.
Article126 days ago